U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Approval Year

2020
691
Substance Class Protein
Created
by admin
on Wed Apr 02 00:22:39 GMT 2025
Edited
by admin
on Wed Apr 02 00:22:39 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1-2-KAPPA
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
QQA9MLH692
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
MOR-00208
Preferred Name English
TAFASITAMAB
INN  
Official Name English
TAFASITAMAB [MI]
Common Name English
MOR-208
Common Name English
XMAB5574
Common Name English
TAFASITAMAB [USAN]
Common Name English
HUMANIZED FC ENGINEERED MONOCLONAL ANTIBODY AGAINST CD19
Common Name English
IMMUNOGLOBULIN, ANTI-(HUMAN CD19 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL MOR00208 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL MOR00208 .KAPPA.-CHAIN, DIMER
Common Name English
MOR00208
Code English
Tafasitamab [WHO-DD]
Common Name English
XMAB-5574
Common Name English
tafasitamab [INN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 456014
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
EU-Orphan Drug EU/3/17/1962
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
FDA ORPHAN DRUG 427914
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
Code System Code Type Description
WIKIPEDIA
Tafasitamab
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
PRIMARY
SMS_ID
100000183311
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
PRIMARY
DRUG BANK
DB15044
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
PRIMARY
CAS
1422527-84-1
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
PRIMARY
RXCUI
2387211
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
PRIMARY
MERCK INDEX
m12232
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
PRIMARY
INN
10835
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
PRIMARY
NCI_THESAURUS
C95768
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
PRIMARY
DAILYMED
QQA9MLH692
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
PRIMARY
USAN
GH-86
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
PRIMARY
FDA UNII
QQA9MLH692
Created by admin on Wed Apr 02 00:22:39 GMT 2025 , Edited by admin on Wed Apr 02 00:22:39 GMT 2025
PRIMARY
From To
1_22 1_96
1_148 1_204
1_265 1_325
1_371 1_429
1_224 3_219
1_230 2_230
1_233 2_233
2_22 2_96
2_148 2_204
2_265 2_325
2_371 2_429
2_224 4_219
3_23 3_93
3_139 3_199
4_23 4_93
4_139 4_199
Glycosylation Link Type Site
N 1_301
N 2_301
Related Record Type Details
B-LYMPHOCYTE ANTIGEN CD19
TARGET->LIGAND
Scientific Literature
TAFASITAMAB-CXIX
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
TAFASITAMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966